Results 111 to 120 of about 510,697 (405)

Health professional views on the assessment and management of foot problems in people with psoriatic arthritis in Australia and New Zealand: a qualitative investigation

BMC Musculoskeletal Disorders, 2019
Background Active foot disease persists in a high proportion of people with psoriatic arthritis despite the availability of pharmacological and non-pharmacological interventions to modify the course of the disease.
Kate Carter, Steven Walmsley, Keith Rome, Deborah E. Turner   +3 more
doaj   +1 more source

Foreword: Seminars in Research 2014 Joint Experiences in Rheumatology and Dermatology [PDF]

, 2016
..
Costanzo, Antonio, Spinelli, FRANCESCA ROMANA   +1 more
core   +1 more source

Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices. [PDF]

, 2020
ObjectiveIt is unclear if biosimilars of biologics for inflammatory arthritis are realizing their promise to increase competition and improve accessibility.
Bansback, Nick, Curtis, Jeffrey R, Evans, Michael, He, Zeling, Huang, Jie, Johansson, Tracy, Liao, Katherine P, Michaud, Kaleb, Schmajuk, Gabriela   +8 more
core   +1 more source

Mucosal‐Associated Invariant T Cells in Rheumatic Diseases

Arthritis &Rheumatology, EarlyView.
Mucosal‐associated invariant T (MAIT) cells are innate‐like T cells defined by their semi‐invariant T cell receptor and restriction by the major histocompatibility complex class I–related molecule (MR1). These cells are primarily activated by microbial‐derived metabolites presented by MR1 or by cytokines.
Manon Lesturgie‐Talarek, Virginie Gonzalez, Lucie Beaudoin, Noémie Sénot, Corinne Miceli‐Richard, Yannick Allanore, Agnès Lehuen, Jerôme Avouac   +7 more
wiley   +1 more source

CLINICAL OUTCOME MEASURES OF PSORIASIS

Reumatismo, 2011
Several tools have been introduced in clinical trials to quantify the severity and the response to a given therapeutic regimen of both psoriasis and psoriatic arthritis. Each method present specific advantages and limitations.
E. Berardesca, C. Bonifati
doaj   +1 more source

Viewpoint on handling anti-TNF failure in psoriasis [PDF]

, 2013
An association among the occurrence of antidrug antibodies (ADAs), diminished trough serum drug levels (TSDLs) and non-response or loss of response has been described for several tumor necrosis factor alpha (TNF) blocking agents in a variety of diseases,
BRACKE, STEFANIE, Lambert, Jo
core   +1 more source

2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis

Arthritis care & research, 2018
Objective: To develop an evidence-based guideline for the pharmacologic and nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF ...
Jasvinder A. Singh, G. Guyatt, A. Ogdie, D. Gladman, C. Deal, A. Deodhar, M. Dubreuil, Jonathan Dunham, M. E. Husni, Sarah Kenny, J. Kwan-Morley, Janice Lin, Paula Marchetta, Philip J. Mease, J. F. Merola, Julie Miner, Christopher T. Ritchlin, B. Siaton, Benjamin J. Smith, A. V. Van Voorhees, A. Jonsson, A. A. Shah, Nancy M. Sullivan, Marat Turgunbaev, Laura C Coates, A. Gottlieb, M. Magrey, W. Nowell, A. Orbai, Soumya Reddy, J. Scher, E. Siegel, M. Siegel, Jessica A Walsh, Amy S. Turner, J. Reston   +35 more
semanticscholar   +1 more source

Early Psoriatic Arthritis [PDF]

Rheumatic Disease Clinics of North America, 2015
Skin psoriasis is a major risk factor for the development of psoriatic arthritis. Recent studies have shown that delayed diagnosis is associated with long-term adverse outcomes. Screening questionnaires have revealed a potential burden of undiagnosed disease. Lifestyle factors and genetic and soluble biomarkers have come under scrutiny as risk factors.
openaire   +2 more sources

Autoantibody Response Toward Chromatin in Patients With Juvenile Idiopathic Arthritis

Arthritis &Rheumatology, EarlyView.
Objective Patients with juvenile idiopathic arthritis (JIA) frequently exhibit antinuclear antibodies (ANAs), but the specific antigen target recognized by them and the presence of additional autoantibody specificities in patients with JIA remains elusive.
Viola Pitkänen, Terhi Remes‐Pakarinen, Paula Vähäsalo, Milja Möttönen, Minna‐Maija Grönlund, Miika Arvonen, Mikael Knip, Riitta Veijola, Jorma Toppari, Jorma Ilonen, Johanna Lempainen, Anna‐Mari Schroderus, Liisa Kröger, Tuure Kinnunen   +13 more
wiley   +1 more source

COVID-19 in patients with psoriasis: A Latin American case series

JAAD International, 2021
Isabela Campo-Slebi, MD, María Fernanda Meza-Corso, MD, Paola Cárdenas, MD, Juan Raúl Castro-Ayarza, MD, Cesar González, MD, Carolina Cortés, MD, Manuel Franco, MD, Fernando Valenzuela, MD   +7 more
doaj   +1 more source